Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV

Antiviral Therapy

Volumn 14, Issue 6, 2009, Pages 771-779

  Young, Jim ^a   Bucher, Heiner C ^a,b   Guenthard, Huldrych F ^c   Rickenbach, Martin ^d   Fux, Christoph A ^e   Hirschel, Bernard ^f   Cavassini, Matthias ^d   Vernazza, Pietro ^g   Bernasconi, Enos ^h   Battegay, Manuel ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SWITZERLAND;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; PYRIMIDINONES;

EID: 72049130542     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1291     Document Type: Article

References (37)

1. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
2. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106. (Pubitemid 351679596)
3. Echeverria P, Carosi G, Galves J, et al. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ ritonavir, administered with abacavir/lamivudine (Kivexa), in naive patients: a multicentre, randomized study. 8th International Congress on Drug Therapy in HIV Infection. 12-16 November 2006, Glasgow, UK. Abstract P7.
4. 3 in Mexico. 17th International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract TUAB0104.
5. Manfredi R, Calza L, Chiodo F. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. AIDS 2004; 18:2331-2333. (Pubitemid 39620229)
6. Torti C, Quiros-Roldan E, Regazzi M, et al. Early virological failure after tenofovir plus didanosine plus efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. J Antimicrob Chemother 2005; 56:190-195.
7. De Luca A, Cozzi-Lepri A, Antinori A, et al. Lopinavir/ ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison. Antivir Ther 2006; 11:609-618.
8. Domingo P, Suarez-Lozano I, Torres F, et al. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. J Antimicrob Chemother 2008; 61:1348-1358.
9. Pulido F, Arribas J, Moreno S, et al. Similar virologic and immunologic response to efavirenz or lopinavir/ritonavir-based HAART in a large cohort of antiretroviral-naive patients with advanced HIV infection. 8th International Congress on Drug Therapy in HIV Infection. 12-16 November 2006, Glasgow, UK. Abstract P9.
10. Soria A, Lazzarin AM. Antiretroviral treatment strategies and immune reconstitution in treatment-naive HIV-infected patients with advanced disease. J Acquir Immune Defic Syndr 2007; 46 Suppl 1:S19-S30.
11. Riddler SA, Haubrich R, Mellors JW. Initial treatment of HIV-1 infection. N Engl J Med 2008; 359:971.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 3 November 2008. Accessed 10 March 2009.) Available from http://www. aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
13. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407-413.
14. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570. (Pubitemid 30660035)
15. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990; 9:1501-1515.
16. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560. (Pubitemid 30660034)
17. Kraemer HC, Blasey CM. Centring in regression analyses: a strategy to prevent errors in statistical inference. Int J Methods Psychiatr Res 2004; 13:141-151.
18. Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190:1860-1868.
19. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002; 21:2917-2930.
20. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol 2004; 57:229-236. (Pubitemid 38456874)
21. Royston P, Sauerbrei W, Altman DG. Modeling the effects of continuous risk factors. J Clin Epidemiol 2000; 53:219-221.
22. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355:1064-1069. (Pubitemid 30162810)
23. Sterne JA, Davey SG. Sifting the evidence-what's wrong with significance tests? BMJ 2001; 322:226-231.
24. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39:1038-1046. (Pubitemid 39313463)
25. Senn S. Statistical issues in drug development. Chichester: Wiley 1997; pp.155.
26. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 2008; 68:567-578.
27. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008; 61:769-773.
28. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33:1417-1423. (Pubitemid 32955198)
29. Haubrich R, Riddler SA, DiRienzo AG, et al. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 38.
30. Young J, Glass TR, Bernasconi E, et al. Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. J Clin Epidemiol 2009; 62:632-641.
31. von Wyl, V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167:1782-1790. (Pubitemid 47403067)
32. Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10:585-591. (Pubitemid 41224950)
33. Rush AJ. Developing the evidence for evidence-based practice. CMAJ 2008; 178:1313-1315.
34. Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA 2006; 296:1286-1289. (Pubitemid 44394901)
35. Greenfield S, Kravitz R, Duan N, Kaplan SH. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 2007; 120 (4) Suppl 1:S3-S9. (Pubitemid 46497038)
36. Grouin JM, Coste M, Lewis J. Subgroup analyses in randomized clinical trials: statistical and regulatory issues. J Biopharm Stat 2005; 15:869-882. (Pubitemid 41022996)
37. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing 2007.